ARS Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ARS Pharmaceuticals,
SPRY Stock   13.59  0.44  3.14%   
ARS Pharmaceuticals,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ARS Pharmaceuticals,'s valuation are provided below:
Gross Profit
90.8 M
Profit Margin
(0.43)
Market Capitalization
1.4 B
Enterprise Value Revenue
10.2196
Revenue
112.3 M
We have found one hundred twenty available fundamental signals for ARS Pharmaceuticals,, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of ARS Pharmaceuticals, prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself next year. Market Cap is likely to drop to about 810.8 M in 2025. Enterprise Value is likely to drop to about 723.5 M in 2025

ARS Pharmaceuticals, Total Revenue

93.61 Million

Check ARS Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 197.6 K, Gross Profit of 92.6 M or Other Operating Expenses of 96.8 M, as well as many indicators such as Price To Sales Ratio of 10.9, Dividend Yield of 0.0 or PTB Ratio of 3.78. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals, Valuation or Volatility modules.
  
Build AI portfolio with ARS Stock
Check out the analysis of ARS Pharmaceuticals, Correlation against competitors.
For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals, guide.

ARS Pharmaceuticals, Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets368.7 M351.2 M99.1 M
Slightly volatile
Short and Long Term Debt Total39.9 K42 K6.6 M
Slightly volatile
Other Current Liabilities13.6 M13 M2.7 M
Slightly volatile
Total Current Liabilities24.6 M23.4 M8.5 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.1 M4 M
Slightly volatile
Accounts Payable10.4 M9.9 M2.3 M
Slightly volatile
Cash70.2 M50.8 M42.4 M
Slightly volatile
Non Current Assets Total17.7 M16.9 M6.7 M
Pretty Stable
Cash And Short Term Investments329.7 M314 M88.9 M
Slightly volatile
Common Stock Shares Outstanding57.7 M102.4 M43.1 M
Slightly volatile
Liabilities And Stockholders Equity368.7 M351.2 M99.1 M
Slightly volatile
Non Current Liabilities Total74.5 M70.9 M19.2 M
Slightly volatile
Other Current Assets6.2 M5.9 M1.6 M
Slightly volatile
Other Stockholder Equity398.9 M379.9 M97.3 M
Slightly volatile
Total Liabilities99.1 M94.4 M27.7 M
Slightly volatile
Total Current Assets351 M334.3 M92.5 M
Slightly volatile
Short Term Debt39.9 K42 K3.2 M
Slightly volatile
Other Liabilities2.5 M2.6 M3.3 M
Slightly volatile
Current Deferred Revenue931 K557 K2.6 M
Slightly volatile
Other Assets3.6 M3.4 M809.2 K
Slightly volatile
Long Term Debt5 M4.4 M6.6 M
Slightly volatile
Net Receivables9.6 M9.2 M1.5 M
Slightly volatile
Property Plant And Equipment Gross829.6 K1.3 M306.9 K
Slightly volatile
Short and Long Term Debt3.3 M4 M2.9 M
Slightly volatile
Capital Stock8.6 K9 K171.7 K
Slightly volatile
Non Current Liabilities Other83.8 M79.8 M15 M
Slightly volatile
Net Working Capital194.3 M310.9 M78.7 M
Slightly volatile
Common Stock8.6 K9 K155.8 K
Slightly volatile
Property Plant Equipment383.2 K378.4 K147.8 K
Slightly volatile
Common Stock Total Equity7.2 K8.1 K8.8 K
Slightly volatile
Capital Surpluse279.5 M314.5 M342.9 M
Slightly volatile
Intangible Assets4.6 M7.7 M1.3 M
Slightly volatile

ARS Pharmaceuticals, Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization197.6 K208 K958.9 K
Slightly volatile
Other Operating Expenses96.8 M92.2 M32.9 M
Slightly volatile
Research Development20.3 M19.6 M16.7 M
Slightly volatile
Cost Of Revenue928.1 K977 K1.9 M
Very volatile
Total Operating Expenses95.8 M91.3 M30.9 M
Slightly volatile
Interest Expense1 M959.1 K253.7 K
Slightly volatile
Selling General Administrative75.3 M71.7 M16.5 M
Slightly volatile
Total Revenue93.6 M89.1 M24.1 M
Slightly volatile
Selling And Marketing Expenses109.2 K65.7 K178 K
Slightly volatile
Non Operating Income Net Other667.2 K750.6 K818.4 K
Slightly volatile

ARS Pharmaceuticals, Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow65.2 M71 M39 M
Slightly volatile
Capital Expenditures591.1 K563 K414.8 K
Pretty Stable
Total Cash From Financing Activities56 M72.4 M35.5 M
Slightly volatile
End Period Cash Flow70.2 M50.8 M42.4 M
Slightly volatile
Stock Based Compensation7.9 M14.5 M5 M
Slightly volatile
Change To Netincome5 M8.1 M4.4 M
Slightly volatile
Sale Purchase Of Stock456 K513 K559.3 K
Slightly volatile
Cash And Cash Equivalents Changes120.4 M135.4 M147.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.911.47161.2 K
Slightly volatile
Days Sales Outstanding35.6437.5117632
Slightly volatile
Stock Based Compensation To Revenue0.150.16319.7054
Slightly volatile
EV To Sales10.3610.9021 K
Slightly volatile
Inventory Turnover0.150.170.184
Slightly volatile
Days Of Inventory On Hand1.6 K1.8 K1.9 K
Slightly volatile
Payables Turnover0.0940.0991.817
Pretty Stable
Sales General And Administrative To Revenue1.5 K1.4 K281
Slightly volatile
Research And Ddevelopement To Revenue0.210.219643.8929
Slightly volatile
Capex To Revenue0.0060.00630.4108
Slightly volatile
Cash Per Share1.853.23951.4332
Slightly volatile
Days Payables Outstanding3.5 K3.3 K1.1 K
Slightly volatile
Intangibles To Total Assets0.0230.02190.0051
Slightly volatile
Current Ratio20.2814.261714.3775
Slightly volatile
Receivables Turnover15.959.730334.0377
Slightly volatile
Graham Number1.782.02.1767
Slightly volatile
Capex Per Share0.0090.00580.0109
Slightly volatile
Revenue Per Share0.970.91970.4854
Very volatile
Interest Debt Per Share4.0E-44.0E-40.2
Slightly volatile
Debt To Assets1.0E-41.0E-40.2534
Slightly volatile
Operating Cycle1.9 K2 K871
Slightly volatile
Days Of Payables Outstanding3.5 K3.3 K1.1 K
Slightly volatile
Effective Tax Rate0.02780.03130.0341
Slightly volatile
Long Term Debt To Capitalization0.110.09920.3826
Slightly volatile
Total Debt To Capitalization2.0E-42.0E-40.3123
Pretty Stable
Quick Ratio20.2614.039414.3623
Slightly volatile
Net Income Per E B T0.780.870.9477
Slightly volatile
Cash Ratio2.062.1687.4208
Slightly volatile
Days Of Inventory Outstanding1.6 K1.8 K1.9 K
Slightly volatile
Days Of Sales Outstanding35.6437.5117632
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.090.95841.0127
Pretty Stable
Fixed Asset Turnover79.4583.6295544
Slightly volatile
Debt Ratio1.0E-41.0E-40.2534
Slightly volatile
Price Sales Ratio10.911.47161.2 K
Slightly volatile
Asset Turnover0.220.25390.4998
Slightly volatile
Gross Profit Margin0.580.890.4063
Slightly volatile

ARS Pharmaceuticals, Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap810.8 M1 B1.3 B
Slightly volatile
Enterprise Value723.5 M971.9 M1.2 B
Slightly volatile

ARS Fundamental Market Drivers

Cash And Short Term Investments314 M

ARS Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ARS Pharmaceuticals, Financial Statements

ARS Pharmaceuticals, investors use historical fundamental indicators, such as ARS Pharmaceuticals,'s revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ARS Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue557 K931 K
Cost Of Revenue977 K928.1 K
Total Revenue89.1 M93.6 M
Stock Based Compensation To Revenue 0.16  0.15 
Sales General And Administrative To Revenue1.4 K1.5 K
Research And Ddevelopement To Revenue 0.22  0.21 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.92  0.97 
Ebit Per Revenue(0.03)(0.04)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HLNHaleon plc
NVDANVIDIA
INTCIntel

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals,'s price analysis, check to measure ARS Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals, is operating at the current time. Most of ARS Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY